In AUD patients with diabetes who start GLP-1 receptor agonists or SGLT2 inhibitors, do you change the intensity or timing of liver fibrosis monitoring, and which on-treatment signals (labs vs elastography vs clinical events) would you rely on to adjust follow-up?